Dihydroisoquinoline alkaloid compound in purslane as well as extraction and separation method and application of dihydroisoquinoline alkaloid compound

Abstract

The invention belongs to the technical field of extraction and separation of traditional Chinese medicines, and particularly relates to a first-class dihydroquinoline alkaloid compound extracted, separated and identified from purslane and an extraction and separation method thereof. The molecular formula of the first-component compound dihydroquinoline alkaloid is C10H11NO3, and the first-component compound dihydroquinoline alkaloid is named as 6, 7-dihydroxy-3, 4-dihydroxyisoquinoline-2 (1H)-carbaldehydrate, and the structural formula of the first-component compound dihydroquinoline alkaloid is shown in the specification. The invention further provides an extraction and separation method of the first-component compound. Water decoction extraction, macroporous resin column chromatography, ODS column chromatography and a high performance liquid chromatograph are sequentially adopted for separation, purification and preparation. The structure of the compound is determined to be a 6, 7-dihydroxy-3, 4-dihydroxyisoquinoline-2 (1H)-carbaldehyde compound by adopting a mass spectrum analysis method, a hydrogen spectrum analysis method, a carbon spectrum analysis method and a two-dimensional nuclear magnetic spectrum analysis method. The first-component compound has anti-inflammatory activity, anti-cholinesterase activity and anti-oxidation activity. The first-component compound and the salt or derivative thereof can be used as raw materials for drug development and pharmacological activity research.

Description

Technical Field

[0001] The invention belongs to the technical field of traditional Chinese medicine extraction and separation, and in particular relates to a dihydroisoquinoline alkaloid compound in purslane and an extraction and separation method and application thereof. Background Art

[0002] Purslane comes from the dried aerial parts of Portulaca oleracea L., a plant of the Portulacaceae family. As a traditional Chinese medicine in my country, Purslane has a history of thousands of years of use. It is widely distributed, rich in resources, and has very strong adaptability and tenacious vitality. The 2020 edition of the "Pharmacopoeia of the People's Republic of China" lists the dried aerial parts of Purslane as medicine. It tastes sour and cold, and enters the liver and large intestine meridians. It has the effects of clearing away heat and detoxifying, cooling blood and stopping bleeding, and stopping dysentery. It is used for heat-toxic bloody dysentery, carbuncle, furuncle, eczema, erysipelas, snake and insect bites, blood in the stool, hemorrhoids, and metrorrhagia.

[0003] Purslane contains a variety of chemical components, mainly including: alkaloids, flavonoids, organic acids, terpenes, coumarins, polysaccharides, amino acids and minerals. Among them, there are many types of alkaloid compounds in Purslane, such as uracil, adenine, norepinephrine, dopamine, adenosine, N,N-dicyclohexylurea, purslanamide, allantoin, N-trans-feruloyltyramine, p-hydroxyphenylethylamine, Oleracein AE, Oleraindole AG, Oleraisoindole, Portulaceramide A, etc. The chemical components contained in Purslane are closely related to its diverse pharmacological effects. Modern pharmacological studies have shown that Purslane has antioxidant, neuroprotective, anti-inflammatory, antibacterial, anti-tumor, hypoglycemic, liver-protecting and immune-enhancing effects. There are many kinds of chemical components in Purslane and their pharmacological activities are diverse. The development and separation of compounds in Purslane can provide a basis for in-depth research on Purslane. Summary of the invention

[0004] In view of the above problems, the present invention provides a dihydroisoquinoline alkaloid compound extracted from Portulaca oleracea. Studies have shown that the dihydroisoquinoline alkaloid compound has anti-inflammatory activity, anticholinesterase activity and antioxidant activity. At the same time, a simple, rapid, environmentally friendly and high-purity extraction and separation method for the compound of the present invention is provided.

[0005] To achieve the above object, the present invention provides a dihydroisoquinoline alkaloid compound having a molecular formula of C 10 H 11 NO 3 , named 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde according to its structure, and its chemical structure is:

[0006]

[0007] The present invention also provides a method for extracting and separating a dihydroisoquinoline alkaloid compound 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde, comprising the following steps:

[0008] Step 1: Take dried purslane, decoct in water to extract, concentrate the extract, cool to room temperature, and set aside the liquid medicine.

[0009] Step 2: The concentrated solution in step 1 is subjected to a macroporous resin, and eluted with water and ethanol of different concentrations, and the 30% ethanol portion is recovered under reduced pressure to obtain an extract, and a concentrate is obtained for use.

[0010] Step 3: Separate the concentrate in step 2 through an ODS column (Octadecylsilyl, octadecylsilane bonded silica gel filler) using a methanol-water gradient elution, detect by thin layer chromatography, develop color, combine the 30% methanol elution portion and evaporate to dryness to obtain a concentrate for use.

[0011] Step 4: The concentrate obtained in step 3 is separated by ODS column chromatography again, using methanol-water gradient elution, detected by thin layer chromatography, color development, and the 50% methanol elution portion is combined and evaporated to dryness to obtain a concentrate for use.

[0012] Step 5: The concentrate obtained in step 4 is separated and prepared by HPLC (high performance liquid chromatography), and acetonitrile-0.1% formic acid (volume percentage) is used as a mobile phase for isocratic elution to finally obtain the dihydroisoquinoline alkaloid compound 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde of the present invention.

[0013] Furthermore, in step 1, the water decocting and extraction are performed twice, each time for 2 hours, and the amount of water used is 8 to 16 times the amount of the medicinal material.

[0014] Furthermore, in step 2, the macroporous resin is AB-8 macroporous resin, and the volume ratio of ethanol to water is 30:70, 50:50, 70:30 and 100:0 in the elution gradient.

[0015] Furthermore, in step 3, the volume ratio of methanol to water is 10:0, 30:70, 50:50, 70:30 and 100:0 elution gradient; and the ODS particle size is 40-70 μm.

[0016] Furthermore, in step 4, the volume ratio of methanol to water is 10:0, 30:70, 50:50, 70:30 and 100:0 elution gradient; and the ODS particle size is 40-70 μm.

[0017] Furthermore, the ODS pretreatment process in step 3 and step 4 is: soaking in methanol for 24 hours, after loading on the column, washing with methanol until there is no turbidity when dripped into water, and then balancing with the initial mobile phase.

[0018] Furthermore, in step 5, the volume ratio of acetonitrile-0.1% formic acid is 15:85, and the retention time of the compound is 3.979 min.

[0019] The present invention also provides a use of the 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde separated from the purslane medicinal material as described above in the preparation of anti-inflammatory drugs, anticholinesterase drugs and antioxidant drugs.

[0020] Compared with the prior art, the present invention has the following beneficial effects:

[0021] The separation and pharmacological activity research of 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde from purslane in the present invention has not been reported in purslane; the present invention provides a dihydroisoquinoline alkaloid compound derived from purslane and an extraction and separation method for the compound of the present invention, which sequentially adopts water decoction extraction, macroporous resin column chromatography, ODS column chromatography and high performance liquid chromatography for separation, purification and preparation, and successfully extracts and separates a dihydroisoquinoline alkaloid compound, the method has only five operation steps, the operation method is simple and fast, water is used for extraction, the process method is environmentally friendly, and the purity of the compound separated by the method is high, greater than 90%; in addition, studies have shown that the above compounds have anti-inflammatory activity, anti-cholinesterase activity and antioxidant activity; therefore, the compound 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde separated by the present invention and its salts and derivatives can be used as raw materials for drug development and pharmacological activity research. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde of the present invention 1 H-NMR spectrum.

[0023] Figure 26,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde of the present invention 13 C-NMR spectrum.

[0024] Figure 3 It is the DEPT spectrum of 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde of the present invention.

[0025] Figure 4 This is the HSQC spectrum of 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde of the present invention.

[0026] Figure 5 This is the HMBC spectrum of 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde of the present invention.

[0027] Figure 6 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde of the present invention 1 H- 1 H COSY spectrum.

[0028] Figure 7 This is the ROESY spectrum of 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde of the present invention.

[0029] Figure 8 This is a high-resolution mass spectrum of 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde of the present invention. DETAILED DESCRIPTION

[0030] The following examples will help to understand the present invention, but these examples are only for illustrating the present invention, and the present invention is not limited to these contents. The operating methods in the examples are all conventional operating methods in the art.

[0031] Example 1 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde.

[0032] The present invention provides a dihydroisoquinoline alkaloid compound, the molecular formula of which is C 10 H 11 NO 3 , named 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde, with the chemical structure:

[0033]

[0034] Table 1 shows the NMR data of 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde. The solvent used for NMR is CD 3 OD.

[0035] Table 1 NMR data of 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde.

[0036]

[0037] 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde: brown powder, easily soluble in methanol, slightly soluble in water, after being spotted on a silica gel thin layer plate, the spots appear orange-yellow when sprayed with dilute potassium bismuth iodide test solution, indicating that the compound is an alkaloid component. 1 H-NMR, 13 C-NMR and HR-ESI-TOF-MS signals indicate that the possible molecular formula of the compound is C 10 H 11 NO 3 , the unsaturation degree is 6. HR-ESI-TOF-MS gives m / z 194.0817 [M+H] + The quasi-molecular ion peak of is 194.0817. 1 In H-NMR, δ H 8.16 (1H, s, H-9) suggests that there may be aldehyde hydrogen in the structure, δ H 6.57 (1H, m, H-4) and δ H 6.57 (1H, m, H-7) suggests that there are two aromatic hydrogen atoms in the structure, δ H 4.50(2H,s,H-8),δ H 3.67(2H,t,J=6Hz,12Hz,H-2), δ H2.76 (2H, t, J = 6 Hz, 12 Hz, H-3) suggests that there are three methylene groups in the structure. HMBC shows that H-4 and C-6 (δ C 143.97), C-7a(δ C 122.09), H-7 and C-5 (δ C 144.06), C-3a(δ C 124.57), indicating the presence of a tetrasubstituted benzene ring structure. Since C-5 and C-6 are located in the low field region, it is speculated that there are hydroxyl substitutions at the C-5 and C-6 positions; H-2 is related to C-3a, C-8 (δ C 31.40), H-3 is related to C-7a, H-8 is related to C-2 (δ C 43.54) and C-3a. Since C-2 and C-8 are located in the low field region, it is speculated that C-2 and C-8 are connected to heteroatoms. It is speculated that there may be a piperidine ring structure in the structure, and C-3a and C-7a are shared with the benzene ring. In addition, H-3 is related to C-4, and H-8 is related to C-7, which further indicates that the piperidine ring is connected to the benzene ring, that is, dihydroquinoline exists in the structure; H-9 is related to C-2 and C-8, indicating that the aldehyde group is connected to the N of the piperidine ring. Combined with the molecular weight of the HR-ESI-TOF-MS spectrum, it can be determined that this first-class compound has the above structure. The spectrum shows double signals, which is caused by the isomerization of the CN bond rotation of formamide.

[0038] The present invention also provides a method for extracting and separating 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde, which specifically comprises the following steps:

[0039] Step 1: Weigh 250 kg of dried purslane medicinal materials, use water decoction to extract, the amount used is 10 times the medicinal material, extract twice, each time for 2 hours, combine the extracts, heat and concentrate, cool to room temperature, and obtain the medicinal solution for use.

[0040] Step 2: evaporate the drug solution obtained in step 1 to dryness, separate it through AB-8 macroporous resin column chromatography, use ethanol-water (30:70, 50:50, 70:30 and 100:0, v:v) gradient elution, collect the 30% ethanol portion, recover it to the extract under reduced pressure, and obtain the concentrate for use.

[0041] Step 3: Separate the concentrate in step 2 through a pretreated ODS column with a filler particle size of 40 to 70 μm, and use methanol-water (10:0, 30:70, 50:50, 70:30 and 100:0, v:v) gradient elution, detect by thin layer chromatography, develop color, combine the 30% methanol elution fractions, concentrate to dryness under reduced pressure, and set aside.

[0042] Step 4: The obtained product in step 3 is separated by pre-treated ODS column chromatography, the filler particle size is 40-70 μm, and gradient elution is performed with methanol-water (10:0, 30:70, 50:50, 70:30 and 100:0, v / v), and detection is performed by thin layer chromatography, color development, and the 50% methanol elution part is combined, concentrated to dryness under reduced pressure, and used for standby. The ODS pretreatment process is to soak in methanol for 24 hours, after loading the column, wash with methanol until there is no turbidity when dripped into water, and then balance with the initial mobile phase.

[0043] Step 5: The obtained fraction in step 4 was separated and prepared by HPLC, using acetonitrile and 0.1% formic acid in a volume ratio of 15:85 as the mobile phase and detection wavelengths of 210 and 254 nm to separate and prepare the new natural product 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde of the present invention; the purity determined by normalization method was 95%.

[0044] Example 2 Anti-inflammatory effect of 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde.

[0045] 1Main materials.

[0046] 1.1 Drugs and reagents: The new natural product used in the experiment was prepared by the above method with a purity of 95%. DMEM high-glucose medium, fetal bovine serum (Hyclone, USA); penicillin and streptomycin (Hangzhou Sijiqing Company); LPS (Sigma, USA); IL-1β ELISA kit (Cayman, USA); cell lysate.

[0047] 1.2 Cell line: RAW264.7 macrophages (ATCC cell bank, USA).

[0048] 1.3 Grouping: Divided into control group, LPS group and experimental group.

[0049] 2 Experimental methods.

[0050] 2.1 Cell culture: Add 10% fetal bovine serum and 1% antibiotics (100 U / mL penicillin and 100 μg / mL streptomycin) to DMEM high-glucose medium and store at 4°C.

[0051] 2.2 CCK-8 assay for cell viability: The three groups of RAW264.7 macrophages in logarithmic growth phase were inoculated in 96-well culture plates at a cell density of 1×10 4 pcs / mL, 100 μL per well, 37°C, 5% CO 2After culturing overnight under the conditions, different concentrations of the compound of the present invention, 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde (5μM~50μM) were added to the experimental group. After incubation for 1 hour, LPS with a concentration of 1μg / mL was added to the LPS group and the experimental group, and a zero adjustment group (culture solution containing DMSO solvent) was set up. Each group had 3 replicate wells to investigate the effect of the addition of drugs on the cells. After the cells in the above groups were cultured for 24 hours, 10μL of CCK-8 was added to the cells in each well at 37℃ and 5% CO 2 After incubation for 4 h under the same conditions, the absorbance of each well was measured at a wavelength of 450 nm using an ELISA reader.

[0052] 2.3ELISA method for determination of inflammatory factor IL-1β: RAW264.7 macrophages in the logarithmic growth phase were inoculated in 24-well culture plates at a cell density of 1×10 5 pcs / mL, 1 mL per well, temperature 37°C, 5% CO 2 After overnight culture under the same conditions, the experimental group was added with the compound of the present invention 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde (1μM~20μM) and cultured for 1h, and then LPS (final concentration of 1μg / mL) was added to each well and incubated for 24h. Each group was treated with 3 wells. The IL-1β content was determined by ELISA.

[0053] 3 Experimental results.

[0054] The experimental results show that the compound 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde of the present invention has no effect on the proliferation of LPS-induced macrophages RAW264.7; it can effectively inhibit the secretion of excessive inflammatory cytokine IL-1β produced by LPS-induced macrophages RAW264.7 in a concentration-dependent manner.

[0055] The results of the relative cell survival rate experiment are shown in Table 2.

[0056] Table 2 Effect of compound 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde on the relative survival rate of RAW264.7 macrophages.

[0057]

[0058] The results of ELISA determination of inflammatory factor IL-1β are shown in Table 3.

[0059] Table 3 Effects of compound 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde on the IL-1β content secreted by RAW264.7 cells induced by LPS (mean±standard deviation, n=3).

[0060]

[0061] Note: * P<0.05 compared with the control group. # P<0.05 compared with LPS group.

[0062] Example 3 Anticholinesterase effect of 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde.

[0063] 1Main materials.

[0064] 1.1 Drugs and reagents: The new natural products used in the experiment were prepared by the above method with a purity of 95%. Physostigmine (Shanghai Hanxiang Biotechnology Co., Ltd.), acetylcholine iodide (ATCI) and acetylcholinesterase (AChE) (Dalian Meilun Biotechnology Co., Ltd.), dithiodinitroformic acid (DTNB) (Shanghai Jinshui Biotechnology Co., Ltd.), disodium hydrogen phosphate and sodium dihydrogen phosphate (Shanghai Sinopharm Reagent Co., Ltd.).

[0065] 1.2 Experimental instruments and equipment: HBS-1096A96-well microplate reader (Nanjing Detie Experimental Equipment Co., Ltd.), 1 / 100,000 balance (METTLER, Switzerland), HH-4 digital display constant temperature water bath (Jiangsu Jintan Ronghua Instrument Manufacturing Co., Ltd.).

[0066] 2 Experimental methods.

[0067] In this experiment, the anticholinesterase activity of each compound was determined according to the modified Ellman method. 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde and physostigmine were accurately weighed and prepared into five series of sample solutions with concentrations of 31.25μM, 62.5μM, 125μM, 250μM and 500μM using methanol. The specific operation is as follows: add 140 μL of phosphate buffered saline (0.1M, pH=8.0, containing 0.1 mol / L disodium hydrogen phosphate and sodium dihydrogen phosphate), 20 μL of sample solution, 15 μL of AChE (0.2U / mL) to a 96-well ELISA plate, incubate at 37°C for 10 minutes, add 10 μL of ATCI (4mmol / L) and 10 μL of DTNB (15mmol / L), incubate at 37°C for 20 minutes, place the 96-well plate in an ELISA instrument, and measure the absorbance of each group of samples at a wavelength of 405nm. Among them, methanol was used instead of the sample solution as the blank group, and physostigmine was used instead of the sample solution as the positive control group. The cholinesterase inhibition rate of each compound was calculated according to the following formula (A represents absorbance):

[0068] Inhibition rate (%) = (A 空白 -A 样品 ) / A 空白 ×100%

[0069] 3 Experimental results.

[0070] The experimental results show that the first compound 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde of the present invention exhibits certain anticholinesterase activity, and the inhibitory effect on cholinesterase increases with the increase of the compound concentration, showing a dose-dependent trend.

[0071] The anticholinesterase activity of the first compound of the present invention, 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde, is shown in Table 4.

[0072] Table 4 Anticholinesterase activity of compound 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde.

[0073]

[0074] Example 4 Antioxidant effect of 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde.

[0075] 1Main materials.

[0076] 1.1 Drugs and reagents: The new natural products used in the experiment were prepared by the above method with a purity of 95%. 1,1-Diphenyl-2-picrylhydrazyl free radical (DPPH) (Sigma, USA), butylated hydroxyanisole (BHA) (Shanghai Xiangrui Biological Co., Ltd.), methanol (chromatographic grade, Tianjin Kaixin Chemical Industry Co., Ltd.).

[0077] 1.2 Experimental instruments and equipment: Hitachi UV-3010 ultraviolet-visible spectrophotometer (Hitachi, Japan), 1 / 100,000 balance (METTLER, Switzerland).

[0078] 2 Experimental methods.

[0079] In this experiment, the DPPH free radical scavenging method was used to determine the antioxidant activity of each compound. 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde and BHA were accurately weighed and prepared into five series of sample solutions with concentrations of 12.5μM, 25μM, 50μM, 100μM and 200μM with methanol. In addition, the DPPH solution was prepared as needed, and an appropriate amount of DPPH was accurately weighed and prepared into a solution with a concentration of 80μM with methanol. The whole process was protected from light. The specific operation is as follows: 1mL of the sample solution was fully mixed with 1mL of the DPPH solution, and placed at room temperature and in a light-proof environment for 10min. After setting the detection wavelength of the ultraviolet spectrophotometer to 517nm, the absorbance value of the sample was measured. Among them, methanol was used instead of the sample solution as the blank group, BHA was used instead of the sample solution as the positive control group, and a mixed solution of 1mL of methanol and 1mL of the sample solution was used as the control group. The DPPH scavenging rate of each compound was calculated according to the following formula (A represents absorbance):

[0080] DPPH clearance rate (%) = (1-(A 样品 -A 对照 ) / A 空白 )×100%

[0081] 3 Experimental results.

[0082] The experimental results show that the first compound 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde of the present invention exhibits certain antioxidant activity, and the antioxidant effect increases with the increase of the compound concentration, showing a dose-dependent trend.

[0083] The antioxidant activities of the first compounds of the present invention are shown in Table 5.

[0084] Table 5 Antioxidant activity of compound 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde.

[0085]

[0086] In summary, the present invention provides a compound 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde and an extraction and separation method thereof, which uses water decoction extraction, macroporous resin column chromatography, ODS column chromatography and high performance liquid chromatography for separation, purification and preparation, and successfully extracts and separates a dihydroquinoline alkaloid compound. The operation method is simple, rapid and environmentally friendly, and the compound separated by the method has a high purity. Since the obtained compound is extracted from the commonly used traditional Chinese medicine Portulaca oleracea, it has anti-inflammatory activity, anticholinesterase activity and antioxidant activity; therefore, the new natural product 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde and its salts and derivatives of the present invention can provide ideas for drug development and have broad development prospects.

Claims

1. A dihydroquinoline alkaloid compound isolated from Portulaca oleracea, characterized in that: The molecular formula is: C 10 H 11 NO3, named according to the structural formula 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1 H )-carbaldehyde, the chemical structure is: 。 2. A method for extracting and separating dihydroquinoline alkaloid compounds isolated from Portulaca oleracea, characterized in that: The specific steps include: Step 1: Take dried purslane medicinal material, decoct it in water, concentrate the extract, cool it to room temperature, and obtain the medicinal solution for later use; Step 2: The concentrated solution in step 1 is subjected to a macroporous resin, and eluted with water and ethanol of different concentrations, and the 30% ethanol portion is recovered under reduced pressure to obtain an extract, and a concentrate is obtained for standby use; Step 3: Separate the concentrate in step 2 through an ODS column, use a methanol-water gradient elution, detect by thin layer chromatography, develop color, combine the 30% methanol elution portion and evaporate to dryness to obtain a concentrate for use; Step 4: The concentrate obtained in step 3 is separated by ODS column chromatography, eluted by methanol-water gradient, detected by thin layer chromatography, and color developed. The 50% methanol elution portion is combined and evaporated to dryness to obtain a concentrate for use; Step 5: The concentrate obtained in step 4 is separated and prepared by HPLC, and acetonitrile-0.1% formic acid (volume percentage) is used as the mobile phase for isocratic elution to finally obtain the compound 6,7-dihydroxy-3,4-dihydroisoquinoline-2(1 H )-carbaldehyde.

3. The extraction and separation method according to claim 2, characterized in that: In the step 1, the extraction is performed by decoction twice, each time for 2 hours, and the amount of water used is 8 to 16 times the amount of the medicinal material.

4. The extraction and separation method according to claim 2, characterized in that: In step 2, the macroporous resin is AB-8 macroporous resin, and the volume ratio of ethanol to water is 30:70, 50:50, 70:30 and 100:0 for gradient elution.

5. The extraction and separation method according to claim 2, characterized in that: In the step 3, the volume ratio of methanol to water is 10:0, 30:70, 50:50, 70:30 and 100:0 for gradient elution; the particle size of ODS is 40-70 μm.

6. The extraction and separation method according to claim 2, characterized in that: In step 4, the volume ratio of methanol to water is 10:0, 30:70, 50:50, 70:30 and 100:0 for gradient elution; the particle size of ODS is 40-70 μm.

7. The extraction and separation method according to claim 2, characterized in that: In step 5, the volume ratio of acetonitrile to 0.1% formic acid is 15:85, and the retention time of the compound is 3.979 min.

8. A method for separating dihydroquinoline alkaloid compounds from Portulaca oleracea as claimed in claim 1, characterized in that: The dihydroquinoline alkaloid compound can be used to prepare anti-inflammatory drugs, anticholinesterase drugs and antioxidant drugs or health products.

Images